Our Pipeline
A growing pipeline of T-SIGn® therapeutics aiming to enable a patient’s immune system to recognize, attack, and clear solid tumors.
Akamis Bio has a growing pipeline of T-SIGn® therapeutics capable of driving the intratumoral expression of a broad range of therapeutic proteins, as well as immunologically active biomolecules which aim to enable a patient’s immune system to recognize, attack, and clear solid tumors.
With more than 200 patients treated across our clinical studies, T-SIGn® therapeutics have demonstrated a consistent safety & tolerability profile, as well as promising preliminary evidence of clinical activity.
Stage
Product
Transgene
Payload
Principal
Mechanism
NG-350A
Two transgenes:
Secreted CD40 agonist monoclonal antibody
CD40 agonism
Phase 1
Phase 2
Phase 3
Research
IND
Enabling
Worldwide Rights
NG-7XX
Three transgenes:
IL-12, IL-15 and a chemokine
T-cell and
NK-cell
activation
Product Concept: Tumor-specific delivery of potent immune cell recruitment & activating agents avoiding systemic toxicity
Product Concept: Tumor-specific delivery of CAR-T targets to enhance the efficacy and/or improve the safety profile of the cell therapy
Undisclosed
Various:
Transgene payload packages including natural and synthetic tumor antigens
CAR T-cell targeting & activation
Undisclosed
NG-348
Two transgenes:
Membrane bound CD80 and anti-CD3 scFv
Direct T-cell engagement
